Repository logo

Browsing by Author "Patel, Vanessa"

Now showing 1 - 2 of 2
  • Anthracyclines versus no anthracyclines in the neoadjuvant strategy for HER2+ breast cancer: real-world evidence
    Publication . Pinho, Inês Soares de; Luz, Paulo; Alves, Lucy; Brás, Raquel Lopes; Patel, Vanessa; Martins, Miguel Esperança; Gonçalves, Lisa; Freitas, Ritas; Simão, Diana; Roldán Galnares, Maria; Fernandes, Isabel; Criado, Silvia Artacho; Gamez Casado, Salvador; Baena Cañada, Jose; Vega, Isabel M. Saffie; Costa, João G.; Fernandes, Ana S.; Sousa, Rita Teixeira de; Costa, Luís
    Deescalation strategies omitting anthracyclines (AC) have been explored in early human epidermal growth factor receptor 2-positive breast cancer (HER2+ EBC), showing similar efcacy regarding pathological complete response (pCR) and long-term outcomes as AC-containing regimens. The standard treatment for this tumor subtype is based on chemotherapy and dual HER2 blockade with trastuzumab and pertuzumab, with AC-containing regimens remaining a frequent option for these patients, even in non-high-risk cases. The primary aim of this study was to assess and compare the efectiveness of neoadjuvant regimens with and without AC used in the treatment of HER2+ EBC in the clinical practice according to the pCR achieved with each.
    2023-07-21Journal article Open access Show more
  • Retro tIming: A multicentric retrospective analysis of immunotherapy timing in metastatic melanoma
    Publication . Gonçalves, Lisa; Goncalves, Duarte; Casanelles, Teresa Esteban; Guerra, Laura Pratas; Menezes, Maria B.; Branco, Vanessa Duarte; Luís, Joana Alves; Simões, Filipa; Gramaça, João; Pinho, Inês S.; Barroso, Tiago; Patel, Vanessa; Martins, Miguel Esperança; Brás, Raquel Lopes; Sousa, Rita Teixeira de; Mansinho, André; Torres, Sofia; Costa, Luis
    Immune checkpoint inhibitors (ICI) targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are now the standard of care in the treatment of metastatic melanoma (mM). The interplay between cancer cells and tumor microenvironment cells (e.g. immune cells) impacts cancer cell survival, local invasion, and metastatic dissemination. Chrono-immunotherapy is an emerging field as circadian oscillations are observed in the immune landscape (e.g immune cell numbers) as well as in the expression of immunotherapy targets (e.g. PD-1).
    2024-06-01Conference object Restricted access Show more